Literature DB >> 23264027

Why I use subcutaneous immunoglobulin (SCIG).

Ralph S Shapiro1.   

Abstract

Immunoglobulin (IgG) replacement is a life-saving treatment for individuals with primary immunodeficiency disease (PIDD). Today, there are many options for IgG replacement, and the choice is an individual one based on many factors. My preference for most patients is the subcutaneous (SCIG) route. It offers many advantages not offered by the intravenous (IVIG) route. These include: 1) independence from hospital-based infusion settings; 2) an alternative for patients with poor venous access; 3) better tolerability in those patients who are not able to tolerate IVIG; 4) flexibility of dosing; 5) ease of administration; 6) a very low side-effect profile; 7) a comparatively more even, almost physiological, IgG level; 8) less cost to administer than IVIG; and 9) improved quality of life in patients treated with SCIG compared with those treated with IVIG. For most patients with PIDD who require IgG replacement, SCIG offers advantages not available with IVIG.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23264027     DOI: 10.1007/s10875-012-9853-2

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  8 in total

1.  Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion.

Authors:  A Gardulf; L Hammarström; C I Smith
Journal:  Lancet       Date:  1991-07-20       Impact factor: 79.321

2.  The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy.

Authors:  H M Chapel; G P Spickett; D Ericson; W Engl; M M Eibl; J Bjorkander
Journal:  J Clin Immunol       Date:  2000-03       Impact factor: 8.317

3.  Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies.

Authors:  Melvin Berger; Mikhail Rojavin; Peter Kiessling; Othmar Zenker
Journal:  Clin Immunol       Date:  2011-01-23       Impact factor: 3.969

4.  Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home.

Authors:  Ann Gardulf; Uwe Nicolay; Dipl Math; Oscar Asensio; Ewa Bernatowska; Andreas Böck; Beatriz T Costa-Carvalho; Carl Granert; Stefan Haag; Dolores Hernández; Peter Kiessling; Jan Kus; Nuria Matamoros; Tim Niehues; Sigune Schmidt; Ilka Schulze; Michael Borte
Journal:  J Allergy Clin Immunol       Date:  2004-10       Impact factor: 10.793

5.  Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease.

Authors:  Suzanne Skoda-Smith; Troy R Torgerson; Hans D Ochs
Journal:  Ther Clin Risk Manag       Date:  2010-02-02       Impact factor: 2.423

Review 6.  Subcutaneous immunoglobulin replacement in primary immunodeficiencies.

Authors:  Melvin Berger
Journal:  Clin Immunol       Date:  2004-07       Impact factor: 3.969

Review 7.  Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century.

Authors:  Meredith L Moore; James M Quinn
Journal:  Ann Allergy Asthma Immunol       Date:  2008-08       Impact factor: 6.347

8.  Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin.

Authors:  Anders Fasth; Jeanette Nyström
Journal:  J Clin Immunol       Date:  2008-02-07       Impact factor: 8.317

  8 in total
  14 in total

Review 1.  An update on the use of immunoglobulin for the treatment of immunodeficiency disorders.

Authors:  Stephanie Albin; Charlotte Cunningham-Rundles
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

2.  Design and Evaluation of the Highly Concentrated Human IgG Formulation Using Cyclodextrin Polypseudorotaxane Hydrogels.

Authors:  Taishi Higashi; Anna Tajima; Naoko Ohshita; Tatsunori Hirotsu; Irhan Ibrahim Abu Hashim; Keiichi Motoyama; Sawako Koyama; Ruriko Iibuchi; Shiuhei Mieda; Kenji Handa; Tomoaki Kimoto; Hidetoshi Arima
Journal:  AAPS PharmSciTech       Date:  2015-03-17       Impact factor: 3.246

3.  Switching Patients to Home-Based Subcutaneous Immunoglobulin: an Economic Evaluation of an Interprofessional Drug Therapy Management Program.

Authors:  Clemence Perraudin; Aline Bourdin; Francois Spertini; Jérôme Berger; Olivier Bugnon
Journal:  J Clin Immunol       Date:  2016-05-02       Impact factor: 8.317

4.  Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review.

Authors:  Kelly L Stoner; Helena Harder; Lesley J Fallowfield; Valerie A Jenkins
Journal:  Patient       Date:  2014-07-12       Impact factor: 3.883

5.  Intravenous and subcutaneous immunoglobulin replacement: a two-way road. Optimizing healthcare quality in patients with primary immunodeficiencies.

Authors:  Pere Soler-Palacín; Ingrid Gasó-Gago; Aurora Fernández-Polo; Andrea Martín-Nalda; María Oliveras; Julio Martinez-Cutillas; Concepció Figueras
Journal:  J Clin Immunol       Date:  2014-09-05       Impact factor: 8.317

6.  Subcutaneous immunoglobulin replacement therapy in a heart transplant recipient with severe recurrent infections.

Authors:  Javier Carbone; Jesus Palomo; Juan Fernandez-Yañez; Elizabeth Sarmiento
Journal:  Heart Lung Vessel       Date:  2015

7.  Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study.

Authors:  Alessandra Vultaggio; Chiara Azzari; Cinzia Milito; Andrea Finocchi; Claudia Toppino; Giuseppe Spadaro; Antonino Trizzino; Martire Baldassarre; Roberto Paganelli; Viviana Moschese; Annarosa Soresina; Andrea Matucci
Journal:  Clin Drug Investig       Date:  2015-03       Impact factor: 2.859

Review 8.  Health-related quality of life in patients with primary immunodeficiency disease.

Authors:  Fonda Jiang; Troy R Torgerson; Andrew G Ayars
Journal:  Allergy Asthma Clin Immunol       Date:  2015-09-29       Impact factor: 3.406

Review 9.  Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europe.

Authors:  Jacqueline Kerr; Isabella Quinti; Martha Eibl; Helen Chapel; Peter J Späth; W A Carrock Sewell; Abdulgabar Salama; Ivo N van Schaik; Taco W Kuijpers; Hans-Hartmut Peter
Journal:  Front Immunol       Date:  2014-12-12       Impact factor: 7.561

10.  II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies.

Authors:  Ekaterini Simões Goudouris; Almerinda Maria do Rego Silva; Aluce Loureiro Ouricuri; Anete Sevciovic Grumach; Antonio Condino-Neto; Beatriz Tavares Costa-Carvalho; Carolina Cardoso Prando; Cristina Maria Kokron; Dewton de Moraes Vasconcelos; Fabíola Scancetti Tavares; Gesmar Rodrigues Silva Segundo; Irma Cecília Barreto; Mayra de Barros Dorna; Myrthes Anna Barros; Wilma Carvalho Neves Forte
Journal:  Einstein (Sao Paulo)       Date:  2017
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.